Olmedipin Plus (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmedipin Plus is a combination antihypertensive that addresses elevated blood pressure through multiple pathways.

• Hypertension: helps achieve target blood pressure when monotherapy does not provide adequate control.
• Hypertensive urgency: may be used as part of a regimen to lower blood pressure safely under medical supervision.
• Cardiovascular risk reduction: contributes to lowering the risk of stroke and myocardial infarction in patients with high blood pressure.

• Olmedipin Plus combines three agents that act at different points in blood‑pressure regulation. Olmesartan medoxomil blocks the angiotensin II type‑1 receptor, preventing vasoconstriction. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation. Hydrochlorothiazide increases renal sodium and water excretion, reducing plasma volume. The combined actions produce additive reductions in systemic vascular resistance and circulating volume, lowering blood pressure.

Olmedipin Plus may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Peripheral edema, especially of the lower legs
• Headache
• Fatigue
• Increased urination
• Mild electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia or severe electrolyte imbalance
• Angio‑edema, particularly facial or airway swelling
• Liver function abnormalities
• Blood dyscrasias such as neutropenia

When prescribing Olmedipin Plus, clinicians should consider several safety aspects.

• Renal function: assess baseline kidney function and monitor periodically.
• Electrolytes: check serum potassium and sodium levels, especially with diuretic component.
• Cardiovascular status: avoid rapid blood‑pressure drops in patients with recent myocardial infarction.
• Pregnancy: contraindicated in the second and third trimesters; use only if benefits outweigh risks.
• Drug interactions: review concomitant medications for additive hypotensive effects.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmedipin Plus can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of severe hypotension and renal impairment.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyper‑kalemia.
• Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy and affect renal function.
• CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can raise amlodipine concentrations.
• Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.